CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure
Anti-Amyloid Debate Continues With Mixed Readouts
Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody.
You may also be interested in...
Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Tetraneuron Touts Its Multifactorial Gene Therapy Solution For Alzheimer’s
Emerging Company Profile: The biotech plans to enter the clinic next year with a gene therapy targeting the E2F4 protein in the hopes of halting Alzheimer’s disease progression and restoring lost function.
Questions About Gantenerumab Failure Remain, But Roche Is Not Yet Finished With Alzheimer’s
Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.